Exploding numbers of corona cases and new attempts to contain the pandemic – it’s clear that stocks like BioNTech are currently in focus. The Mainz-based company is well advanced in its work on a vaccine against the SARS-CoV-2 virus, the causative agent of COVID-19. They have Pfizer on board as a partner worldwide – with the exception of China, where they work with Fosun Pharma. The vaccine candidate BNT162 is currently being tested in final clinical trials. Around 37,000 participants in the study have already been vaccinated, 28,000 have already received two doses of BNT162. 120 locations worldwide are involved in the clinical study.
Not only investors on the stock exchange who have invested in BioNTech shares are waiting for the results of the studies. In the approval process, things are moving quickly for the Mainz team, and the pace is being pushed. After BioNTech and Pfizer only just launched the Have initiated the “rolling review” submission process for the ongoing review of BNT162b2 at the European Medicines Agency (EMA), this special, accelerated approval process is now also used in Canada.
The process enables BioNTech and Pfizer to submit the safety and efficacy data and information as it becomes available. This enables Health Canada to “begin the review immediately as soon as more information is received in order to expedite the entire review process.” However, this will not be at the expense of safety: Health Canada will “only make a decision on the approval of a vaccine once it has received the necessary evidence for the safety, efficacy and quality of the vaccine,” said BioNTech on Saturday night .